Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

9.46USD
4:00pm EDT
Change (% chg)

$0.24 (+2.60%)
Prev Close
$9.22
Open
$9.24
Day's High
$9.58
Day's Low
$9.16
Volume
775,825
Avg. Vol
994,234
52-wk High
$13.38
52-wk Low
$2.61

ARRY.OQ

Chart for ARRY.OQ

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $1,558.25
Shares Outstanding(Mil.): 169.01
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 47.82 29.72
EPS (TTM): -0.67 -- --
ROI: -56.16 -2.46 13.00
ROE: -343.88 5.18 14.15

BRIEF-Array Biopharma provides NEMO update

* Array Biopharma Inc - Has withdrawn from U.S. FDA division of oncology products 2 its new drug application (NDA) for binimetinib monotherapy

Mar 19 2017

BRIEF-Array Biopharma reports financial results for Q2 of fiscal 2017

* Array Biopharma reports financial results for the second quarter of fiscal 2017

Feb 09 2017

BRIEF-Array BioPharma announces new results from Phase 3 Study in BRAF-Mutant Melanoma

* new results from the pivotal phase 3 COLUMBUS trial of binimetinib plus encorafenib treatment in BRAF-mutant melanoma patients

Nov 09 2016

BRIEF-Array BioPharma Q1 revenue $39.3 mln

* Array BioPharma Inc - Columbus met its primary endpoint in study

Nov 01 2016

BRIEF-Array Biopharma prices public offering at $6.25 per share

* Array Biopharma announces pricing of public offering of common stock

Sep 27 2016

BRIEF-Array Biopharma announces proposed public offering of common stock

* Array Biopharma announces proposed public offering of common stock

Sep 27 2016

CORRECTED-BRIEF-Array Biopharma, Pierre Fabre say Columbus phase 3 study met primary endpoint

* Array Biopharma and Pierre Fabre announce columbus phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma met primary endpoint

Sep 26 2016

More From Around the Web

Competitors

Earnings vs. Estimates